IPO Trending
WINDLASEQ / NSE, BSEListed
Windlas Biotech

Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.

₹448 - ₹460Open
Listed Price₹437.00
Listing Gain-5.00%

Subscription Status

0Updated 20 Oct 2026, 01:30 AM
Subscription PendingExchange subscription breakup is not available yet.

Category-wise demand has not been published yet. Check back after the exchange updates the live subscription feed.

Open Date04 Aug 2021
Close Date06 Aug 2021
Listing Date16 Aug 2021
Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Windlas Biotech IPO Subscription Demand

Live subscription status and bidding analysis for Windlas Biotech (WINDLAS) IPO. The issue is subscribed Tracking Live overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Frequently Asked Questions